Purpose <p>This study evaluated the safety and effectiveness of an intraoral light-emitting diode (LED)-based photobiomodulation (PBM) device to reduce the incidence and severity of oral mucositis (OM) from intensity modulated radiation therapy (IMRT) for head and neck cancer (HNC).</p> Methods <p>This randomized, double-blind, sham-controlled trial enrolled patients with HNC undergoing high-dose IMRT over 6–8 weeks, with or without concurrent chemotherapy. Participants received daily 10-min PBM or sham treatments immediately before IMRT sessions. Assessments were conducted at baseline, daily and weekly during IMRT, and two weeks post-IMRT.</p> Results <p>Eighty-five participants (42 PBM; 43 sham) were enrolled across 12 US sites. No device-related adverse events were observed, and 99.5% of initiated sessions were completed. In the intent-to-treat population, severe OM (WHO Grade ≥ 3) incidence was significantly lower with PBM across six weeks of IMRT (36.8% vs 57.1%; <i>p</i> = 0.046) and at two weeks post-treatment (10.8% vs 36.4%; <i>p</i> = 0.042). In the per-protocol population, the PBM arm reported significantly greater taste preservation (<i>p</i> = 0.034), lower increases in mouth/throat soreness (<i>p</i> = 0.029) and throat pain (<i>p</i> = 0.028) and needed fewer feeding tube placements (<i>p</i> = 0.073) than the control arm.</p> Conclusion <p>Daily intraoral PBM therapy using an LED-based device was safe, well tolerated, and significantly reduced the incidence of severe OM and associated complications in HNC patients undergoing IMRT with or without concurrent chemotherapy. These findings align with guidelines recommending daily intraoral PBM therapy for preventing cancer therapy-related OM, a dose-limiting toxicity for which effective preventive interventions are needed.</p> Trial Registration <p>Clinical Trials.gov Registration Number NCT03972527. Registered on June 3, 2019.</p> Concise Summary <p>Daily intraoral PBM therapy using an LED-based device was safe, well tolerated, and significantly reduced the incidence of severe OM and associated complications in HNC patients undergoing IMRT with or without concurrent chemotherapy. These findings align with guidelines recommending daily intraoral PBM therapy for preventing cancer therapy-related OM, a dose-limiting toxicity for which effective preventive interventions are needed.</p>

Randomized, double-blind, sham-controlled trial of an intraoral photobiomodulation device for oral mucositis and associated complications due to radiotherapy for head and neck cancer

期刊论文
发表日期：

2026年6月26日

查看全文

Kenneth Hu,
Pratish Shah,
M. Connie Nguyen,
Cornelia McCluskey,
Anne Kane,
Roger Ove,
Christopher D. Willey,
Sanford Katz,
Omkar Marathe,
Sasha Valentin,
Jennifer Frustino,
Alessandro Villa,
Sharon Spencer,
Catherine Holtzapfel,
Nathaniel Treister,
Rajesh V. Lalla

摘要

Purpose

This study evaluated the safety and effectiveness of an intraoral light-emitting diode (LED)-based photobiomodulation (PBM) device to reduce the incidence and severity of oral mucositis (OM) from intensity modulated radiation therapy (IMRT) for head and neck cancer (HNC).

Methods

This randomized, double-blind, sham-controlled trial enrolled patients with HNC undergoing high-dose IMRT over 6–8 weeks, with or without concurrent chemotherapy. Participants received daily 10-min PBM or sham treatments immediately before IMRT sessions. Assessments were conducted at baseline, daily and weekly during IMRT, and two weeks post-IMRT.

Results

Eighty-five participants (42 PBM; 43 sham) were enrolled across 12 US sites. No device-related adverse events were observed, and 99.5% of initiated sessions were completed. In the intent-to-treat population, severe OM (WHO Grade ≥ 3) incidence was significantly lower with PBM across six weeks of IMRT (36.8% vs 57.1%; p = 0.046) and at two weeks post-treatment (10.8% vs 36.4%; p = 0.042). In the per-protocol population, the PBM arm reported significantly greater taste preservation (p = 0.034), lower increases in mouth/throat soreness (p = 0.029) and throat pain (p = 0.028) and needed fewer feeding tube placements (p = 0.073) than the control arm.

Conclusion

Daily intraoral PBM therapy using an LED-based device was safe, well tolerated, and significantly reduced the incidence of severe OM and associated complications in HNC patients undergoing IMRT with or without concurrent chemotherapy. These findings align with guidelines recommending daily intraoral PBM therapy for preventing cancer therapy-related OM, a dose-limiting toxicity for which effective preventive interventions are needed.

Trial Registration

Clinical Trials.gov Registration Number NCT03972527. Registered on June 3, 2019.

Concise Summary

Daily intraoral PBM therapy using an LED-based device was safe, well tolerated, and significantly reduced the incidence of severe OM and associated complications in HNC patients undergoing IMRT with or without concurrent chemotherapy. These findings align with guidelines recommending daily intraoral PBM therapy for preventing cancer therapy-related OM, a dose-limiting toxicity for which effective preventive interventions are needed.